作者
Gregory G Schwartz, Michael Szarek, Vera A Bittner, Deepak L Bhatt, Rafael Diaz, Shaun G Goodman, J Wouter Jukema, Megan Loy, Garen Manvelian, Robert Pordy, Harvey D White, Philippe Gabriel Steg
发表日期
2021/5/1
期刊
Diabetes Care
卷号
44
期号
5
页码范围
1219-1227
出版商
American Diabetes Association
简介
OBJECTIVE
In observational data, lower levels of lipoprotein(a) have been associated with greater prevalence of type 2 diabetes. Whether pharmacologic lowering of lipoprotein(a) influences incident type 2 diabetes is unknown. We determined the relationship of lipoprotein(a) concentration with incident type 2 diabetes and effects of treatment with alirocumab, a PCSK9 inhibitor.
RESEARCH DESIGN AND METHODS
In the ODYSSEY OUTCOMES trial alirocumab was compared with placebo in patients with acute coronary syndrome. Incident diabetes was determined from laboratory, medication, and adverse event data.
RESULTS
Among 13,480 patients without diabetes at baseline, 1,324 developed type 2 diabetes over a median 2.7 years. Median baseline lipoprotein(a) was 21.9 mg/dL. With placebo, 10 mg/dL lower baseline lipoprotein(a) was associated …
学术搜索中的文章
GG Schwartz, M Szarek, VA Bittner, DL Bhatt, R Diaz… - Diabetes Care, 2021